– USA, MA – Arbor Biotechnologies Inc v announced the appointment of Mark Angelino to its Board of Directors.
Mark is co-founder and former COO of Generation Bio, and brings significant company building and product development experience to the Arbor Board, given his expertise over the past 20 years working with numerous leading pharmaceutical companies.
“We are excited to have Mark join Arbor’s Board of Directors. Mark has a tremendous breadth of experiences and perspectives on bringing high impact therapeutic products to market,” said Board Chairman, Paul Meister.
About Dr. Mark Angelino
Mark D. Angelino, Ph.D., was a co-founder and COO of Generation Bio from 2016 until 2021. Previously, Mark served as SVP, pharmaceutical sciences, and rare disease franchise head at bluebird bio Inc. from 2012 until 2016. He also served as senior director of research and development and site head in Cambridge, Massachusetts for Baxter Healthcare Corporation from 2010 to 2012.
His experience spans from early company formation through commercialization – including the BLA for gene therapy product, Zynteglo, the first commercial launch for a bioequivalent, ANDA for Glatopa, the sNDA for Integrilin, as well as numerous INDs across small-molecules, biologics, peptides, complex mixture, and gene therapy products.
“I am thrilled to work with the Arbor team and their promising technology. I look forward to helping build Arbor towards novel therapeutic opportunities utilizing the differentiated functional properties of Arbor’s nucleases,” said Mark D. Angelino.
About Arbor Biotechnologies
Arbor Biotechnologies is an early-stage company unlocking nature’s genetic diversity to meet the next generation of challenges in the gene-editing field. Arbor’s proprietary discovery platform has uncovered unique CRISPR enzymes that can power applications across a wide range of industries, including therapeutics and manufacturing.
Since the initiation of its CRISPR gene-editing technology development efforts, Arbor has discovered and engineered innovative technologies, including but not limited to CRISPR Cas13d, Cas12h, and Cas12i nucleases. By harnessing the differentiated capabilities of Arbor’s suite of proprietary gene-editing platforms, Arbor is unlocking therapeutic products and tools to address previously unmet needs. Arbor’s research team, along with its partners and collaborators, are on the cutting edge in exploring the uses of Arbor gene editing technologies for diverse applications across the cell and gene therapy and bio-manufacturing that existing tools are unable to achieve. Following its partnership with Vertex Pharmaceuticals, Arbor recently announced an agreement with Lonza, further validating the breadth of applications of its DNA gene-editing platform.
For more information: https://www.arbor.bio
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
